Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA9161||Alliance||A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011401||Alliance||Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A051301||Alliance||A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221505||Alliance||Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction||Cancer Prevention and Control CIRB||Available to Open|
|A091401||Alliance||Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011502||Alliance||A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|A061402||Alliance||Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|A171601||Alliance||A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer||Cancer Prevention and Control CIRB||Available to Open|
|A091404||Alliance||A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041702||Alliance||A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|